Combined effect of midostaurin and sphingosine kinase-1 inhibitor on FMS-like tyrosine kinase 3 (FLT3) wild type acute myeloid leukemia cells

Abstract

Therapeutic potential of clinically approved FLT3 inhibitor midostaurin has been neglected in wild-type FLT3 positive acute myeloid leukemia (AML). Sphingosine kinase-1 (SK-1) having anti-proliferative functions is studied in various cancers, but not in FLT3 wild-type AML. We aimed to develop new therapeutic strategies to combat FLT3 wild-type AML by combining midostaurin with SK-1 inhibitor (SKI II) in THP1 cells.

Keywords

• apoptosis
• flt3 wild type aml
• midostaurin
• sphingosine kinase
• sphingosine kinase inhibitor
• apoptoz
• flt3 yabanıl tip aml
• midostaurin
• sfingozin kinaz
• sfingozin kinaz inhibitörü